



## SomaLogic's Chief Medical Officer Steve Williams honored with C-Suite Award by the Denver Business Journal

September 26, 2022

BOULDER, Colo., Sept. 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that Chief Medical Officer Steve Williams, M.D., Ph.D., has been named a 2022 C-Suite Award winner by the Denver Business Journal. The honorees in the Denver Business Journal's 2022 C-Suite Awards program are executives who were evaluated by a team of third-party judges on the impact they have made on their organizations, industries and the greater community.

"We are thrilled to recognize Steve's accomplishments with this honor," said SomaLogic Chief Executive Officer Roy Smythe, M.D. "His vision for using proteomics to power objective innovation in healthcare is already driving significant change. His passion for creating new solutions for patients and those who seek to serve them is instrumental to our success as we continue to grow our business. We are very fortunate to have him as part of our team."

One of the many innovations Dr. Williams brought to SomaLogic is revolutionizing study design to incorporate variables like age, gender, geography and ethnicity, and combining this with machine learning to develop accurate diagnostic tests. As a result, SomaLogic can conduct expansive and inclusive studies that are powered by SomaLogic's AI and bioinformatics algorithms along with the company's database of protein measurements on more than 450,000 samples.

Recognizing that the study of proteins could provide a deep understanding of changes in the human body, Dr. Williams's team created a laboratory-developed blood test that can accurately predict the four-year likelihood of heart attack, stroke, heart failure or death in someone with established heart disease or with known elevated risk from diabetes, kidney disease or older age. He led clinical studies that will determine how clinicians will act on these test results to prevent hospitalizations and deaths in people with diabetes. Dr. Williams's team is also applying this knowledge to hospitalized Covid-19 patients to predict the risk of severe illness or death.

Dr. Williams recently published a paper in the journal, *Science Translational Medicine*, on the topic of protein biomarkers in cardiovascular risk. You can find the paper here: <https://www.science.org/doi/abs/10.1126/scitranslmed.abj9625>.

SomaLogic was founded more than 20 years ago with the vision of using large-scale protein measurements to help people optimize their health. In his 12 years at SomaLogic, Dr. Williams led the team at SomaLogic to expand the SomaScan<sup>®</sup> Assay's range from 800 to approximately 7,000 (and soon to be 10,000) proteins and applied the technology in studies that have demonstrated the value of proteomics, the large-scale study of proteins, to life sciences clinical research.

### About SomaLogic

SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic's personalized measurement of important changes in an individual's proteins over time. For more information, visit [www.somalologic.com](http://www.somalologic.com) and follow [@somalologic](https://twitter.com/somalologic) on Twitter.

### Forward Looking Statements Disclaimer

This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "forecast," "guidance," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "continue," "will likely result," "possible," "potential," "predict," "pursue," "target" and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic's control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – "Risk Factors" in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

### Media Contact

Emilia Costales

720-798-5054

[ecostales@somalologic.com](mailto:ecostales@somalologic.com)

**Investor Contacts**

Lauren Glaser

[lglaser@somallogic.com](mailto:lglaser@somallogic.com)

Marissa Bych

Gilmartin Group LLC

[Marissa@gilmartinir.com](mailto:Marissa@gilmartinir.com)